Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CAMP with free AI briefings, catalyst countdowns, and dilution alerts.

CAMP · CAMP4 THERAPEUTICS CORPORATION

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$124.5M Cash on Hand
35.8mo Cash Runway
Follow CAMP by email Get an email when CAMP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CAMP, unsubscribe in one click. Privacy

📣 What CAMP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CMP-002 Nervous System Disease Phase 1/2 · NCT07935135 Not yet recruiting
CMP-CPS-001 Healthy Volunteers Phase 1 · NCT06247670 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CAMP holds $124.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.4M/quarter from operations, an estimated runway of 35.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAMP files for a raise →

👥 Who Owns CAMP

Insiders 24.9% Other 5%+ holders 12.6% Institutions (90 holders) 62.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 7,906,436 12.60% 2026-09-30
Coastlands Capital LP Institution (13G, 5%+) 6,328,175 10.08% 2026-09-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 6,307,636 10.05% 2025-12-31
5AM Partners VI, LLC
10% owner · +3.18M options
Insider 5,869,091 9.35% 2025-09-11
Andrew J. Schwab
Director · +3.22M options
Insider 5,277,216 8.41% 2026-08-27
FMR LLC Institution (13G, 5%+) 4,908,857 7.82% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 4,190,023 6.68% 2026-09-30
Amir Nashat
Director, 10% owner · +28,000 options
Insider 3,932,251 6.27% 2026-08-13
Trails Edge Capital Partners, LP Institution (13G, 5%+) 3,790,636 6.04% 2026-08-03
Polaris Management Co. VII, L.L.C.
10% owner
Includes shares also reported by Amir Nashat, counted once
Insider 909,090 1.45% 2025-09-11
Josh Mandel-Brehm
Chief Executive Officer, Director · +1.01M options
Insider 284,968 0.45% 2026-08-03
Richard A Young
Director · +37,000 options
Insider 186,388 0.30% 2026-08-03

Share count 62,754,200 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CAMP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAMP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.